BioSpace News Archive

Drug Development

Roche Launches New COVID-19 Antibody Test to Support Vaccine Testing

Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark.

September 18, 2020
·
2 min read
·
Mark Terry
BDO to Biotech Companies: Realign Pipelines for Survival Today and Growth Tomorrow

Biotech needs to get tougher on pipeline decisions, according to BDO’s recently released annual Biotech Briefing.

September 18, 2020
·
5 min read
·
Gail Dutton
Drug Development

Genentech Drug Actemra Benefits Patients with COVID-19-Associated Pneumonia, Study Shows

85% of participants in the trial of Actemra were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.

September 18, 2020
·
2 min read
·
Alex Keown
BioForest

Clinical Catch-Up: September 14-18

It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.

September 18, 2020
·
11 min read
·
Mark Terry
Drug Development

ESMO: Merck and AstraZeneca’s 5-Year Lynparza Data in Ovarian Cancer and More

Biopharma companies focused on oncology continue to release data that will be presented at the 2020 virtual meeting of the European Society of Medical Oncology.

September 18, 2020
·
4 min read
·
Alex Keown
Drug Development

Regeneron and Sanofi’s Checkpoint Inhibitor Shines in Phase II BCC Study

Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.

September 18, 2020
·
2 min read
·
Alex Keown
Interest in LAVA’s Potential to Revolutionize Cancer Treatment Evident in $83 Million Series C

LAVA Therapeutics is now financially poised to advance their bispecific antibodies to engage Vγ9Vδ2 T cells in the fight against cancer thanks to an infusion of capital from an oversubscribed $83 million Series C financing.

September 18, 2020
·
2 min read
·
Kate Goodwin
Drug Development

Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020

HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan

September 18, 2020
·
12 min read
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types

September 18, 2020
·
11 min read
Drug Development

Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. and Seattle Genetics, Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.

September 18, 2020
·
15 min read